Adaptimmune Total Liab from 2010 to 2024
| ADAP Stock | USD 0.70 0.04 6.06% |
Total Liabilities | First Reported 2013-06-30 | Previous Quarter 225.4 M | Current Value 237.4 M | Quarterly Volatility 82.5 M |
Check Adaptimmune Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Adaptimmune Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 5.2 M, Interest Expense of 1.6 M or Selling General Administrative of 37.2 M, as well as many indicators such as Price To Sales Ratio of 2.51, Dividend Yield of 0.0 or PTB Ratio of 4.24. Adaptimmune financial statements analysis is a perfect complement when working with Adaptimmune Therapeutics Valuation or Volatility modules.
Adaptimmune | Total Liab |
Latest Adaptimmune Therapeutics' Total Liab Growth Pattern
Below is the plot of the Total Liab of Adaptimmune Therapeutics Plc over the last few years. It is the total amount of all liabilities that a company has, including both short-term and long-term liabilities. Adaptimmune Therapeutics' Total Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Adaptimmune Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Total Liab | 10 Years Trend |
|
Total Liab |
| Timeline |
Adaptimmune Total Liab Regression Statistics
| Arithmetic Mean | 100,038,919 | |
| Geometric Mean | 49,257,631 | |
| Coefficient Of Variation | 99.24 | |
| Mean Deviation | 82,493,940 | |
| Median | 57,905,000 | |
| Standard Deviation | 99,281,900 | |
| Sample Variance | 9856.9T | |
| Range | 259.6M | |
| R-Value | 0.88 | |
| Mean Square Error | 2451.5T | |
| R-Squared | 0.77 | |
| Significance | 0.000018 | |
| Slope | 19,468,599 | |
| Total Sum of Squares | 137996.5T |
Adaptimmune Total Liab History
About Adaptimmune Therapeutics Financial Statements
Adaptimmune Therapeutics shareholders use historical fundamental indicators, such as Total Liab, to determine how well the company is positioned to perform in the future. Although Adaptimmune Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Adaptimmune Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Adaptimmune Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Liabilities | 243.1 M | 255.3 M |
Pair Trading with Adaptimmune Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adaptimmune Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptimmune Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Adaptimmune Stock
| 0.75 | ME | 23Andme Holding | PairCorr |
| 0.91 | VALN | Valneva SE ADR | PairCorr |
| 0.71 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
Moving against Adaptimmune Stock
| 0.63 | KZR | Kezar Life Sciences | PairCorr |
| 0.46 | MLYS | Mineralys Therapeutics, | PairCorr |
| 0.32 | MDGL | Madrigal Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to Adaptimmune Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adaptimmune Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adaptimmune Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adaptimmune Therapeutics Plc to buy it.
The correlation of Adaptimmune Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adaptimmune Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adaptimmune Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Adaptimmune Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Adaptimmune Stock Analysis
When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.